Michael J. Pishvaian, MD, PhD
In the search to establish new therapeutic options for patients with advanced hepatocellular carcinoma (HCC), immunotherapy has become a frontrunner in many clinical trials in the first-line setting, according to Michael J. Pishvaian, MD, PhD.
For example, data presented at the 2018 ESMO Congress on the combination of the PD-L1 inhibitor atezolizumab (Tecentriq) and the VEGF inhibitor bevacizumab (Avastin) showed durable response rates as a frontline regimen for this population. The confirmed investigator-assessed objective response rate (ORR) in the study was 32% per RECIST v1.1 criteria. More than half of responders maintained their response for at least 6 months, and about one-quarter maintained response for at least 12 months.
... to read the full story